Exogenous ketone ester for status epilepticus

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 6 Jan 2023: Trial registered, NCT05674552
  2. 10 Jan 2023: Trial started, NCT05674552

The trials

NCT05674552: Exogenous Ketone Esters for Refractory Status Epileptics

State
Under way
Phase
Phase 2 and Phase 3
People
50 planned
Started
10 Jan 2023
Primary completion
30 Jun 2025
Arms
Study group
Results
None posted
  1. 6 Jan 2023: Trial registered
  2. 10 Jan 2023: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.